Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 4031-4040 Newer>

The Motley Fool October 21, 2004 Tom Taulli	Our Money, Our Lost Identities There are many threats to our pocketbooks in the online world. Entrust's plan to put a stop to it can have a big impact for e-commerce. The company posted revenues of $21.3 million, which was a 6% increase from the same period a year ago.
The Motley Fool October 21, 2004 Jeff Hwang	Looking Up at Caesars There were improved results from all three domestic operating regions. Excluding one-time events and earnings from properties to be sold, adjusted net income climbed 51% to $68 million, or to $0.22 per share from $0.15 per share last year.
The Motley Fool October 21, 2004 W.D. Crotty	Cendant: What a Value The company is producing lots of free cash flow and narrowing its business focus. Both operations (and shareholders) should benefit.
The Motley Fool October 21, 2004 Nathan Slaughter	Is Office Depot Undervalued? The number-two office-supply company meets reduced targets, outlines expansion plans.
The Motley Fool October 21, 2004 Nathan Slaughter	Outback's Earnings Served Cold The steak house has more to offer diners than investors.
The Motley Fool October 21, 2004 Roger Nusbaum	Pictures of Lilly Eli Lilly's numbers get lost in the wake of Merck and Pfizer. While the market waits for drug stocks to recover, investors can collect Lilly's 2.5%, safe, dividend.
The Motley Fool October 21, 2004 Alyce Lomax	Global Focus at UPS Overseas strength boosts United Parcel's third-quarter earnings.
The Motley Fool October 21, 2004 Seth Jayson	SanDisk Stinks, But I'm Not Selling After the stock took a tumble, an investor looks closely at the numbers, listens in on the conference call and decided that panic selling wasn't the thing to do.
The Motley Fool October 21, 2004 Tim Goh	Macromedia Goes Mobile The company had a robust quarter and outlined plans to expand its business. The company makes for a shrewd long-term investment.
The Motley Fool October 21, 2004 Brian Gorman	Merck Is Down But Not Out The pharma's woes may have silver linings. For now, the company's investors might want to sit tight.
<Older 4031-4040 Newer> Return to current articles.